CureVac Reports €371.6 Million Net Income Following GSK Partnership and Strategic Restructuring
核心洞察
CureVac achieved a dramatic financial turnaround with €371.6 million net income in Q3 2024, reversing from a €54 million operating loss in the same period last year.
The German mRNA company received €400 million upfront from GSK in a restructured partnership that transferred control of COVID-19 (搜索) and influenza (搜索) vaccine programs to the British pharmaceutical giant.
CureVac is implementing a 30% workforce reduction and refocusing on oncology, with early clinical data showing antigen-specific T-cell responses in 77% of glioblastoma (搜索) patients treated with its CVGBM cancer vaccine.
CureVac has delivered a remarkable financial turnaround, reporting net income of €371.6 million in the third quarter of 2024 following a comprehensive strategic restructuring and a major partnership revision with GSK. The German mRNA pioneer achieved an operating profit of €368.4 million, a substantial reversal from the €54 million operating loss recorded in the same period the previous year.
The transformation was driven primarily by a restructured collaboration with British pharmaceutical giant GSK, finalized in July 2024, which provided CureVac with a non-refundable upfront payment of €400 million. This transaction propelled third-quarter 2024 revenues to €493.9 million—an extraordinary increase of 2,897% compared to the prior year.
GSK Partnership Reshapes Business Model
Under the revised agreement, GSK assumed complete control over the development, manufacturing, and global commercialization of mRNA vaccine candidates for influenza (搜索) and COVID-19 (搜索), including combination vaccines. While effectively withdrawing CureVac from this competitive segment, the company remains eligible for future milestone payments. An additional €10 million was received in November 2024 when GSK initiated a clinical trial for a combined flu-COVID vaccine.
The partnership restructuring has dramatically improved CureVac's financial position. With liquid assets of €550.9 million by the end of September 2024, compared to €402.5 million at the close of 2023, the company now has a financial runway extending to 2028, eliminating any immediate requirement for additional capital raises.
Operational Restructuring and Cost Reduction
Concurrent with the GSK agreement, CureVac initiated a significant corporate overhaul, reducing its workforce by 30% by the conclusion of 2024. The company is targeting a reduction in operational expenditures exceeding 30% starting in 2025, with personnel cost savings alone projected to reach approximately €25 million annually.
Chief Executive Officer Dr. Alexander Zehnder characterized this restructuring as essential for achieving "operational efficiency" and "strategic alignment," indicating a necessary reorganization to maximize the longevity of remaining capital resources.
Oncology Pipeline Shows Early Promise
As CureVac scales back its vaccine operations, oncology has emerged as the central focus of its development pipeline. During September and November 2024, the company unveiled initial clinical data for its mRNA cancer vaccine, CVGBM, targeting glioblastomas—an aggressive form of brain cancer. The results demonstrated antigen-specific T-cell responses in 77% of treated patients.
The company plans to advance another oncology program targeting non-small cell lung cancer (搜索) into Phase 1 clinical trials during the second half of 2025. Additionally, CureVac is developing a preclinical vaccine targeting urinary tract infections (搜索)—a substantial market opportunity where mRNA-based vaccines may offer significant advantages over traditional protein-based alternatives.
Leadership Strengthening
Strengthening its executive team, CureVac appointed Axel Sven Malkomes as its new Chief Financial Officer in mid-November. The incoming CFO brings more than three decades of financial leadership experience within the biotechnology and pharmaceutical sectors, including previous roles as finance chief at Cardior Pharmaceuticals (搜索) and Medigene. His primary mandate involves leveraging the company's newly established financial stability to make targeted investments in the most promising mRNA therapeutic candidates.
Dr. Zehnder expressed strong confidence in the company's repositioning, stating that CureVac is now "financially positioned to create shareholder value by advancing our portfolio of novel mRNA-based medicines." The strategic direction concentrates resources on oncology, infectious diseases, and other therapeutic areas with significant unmet medical needs.